⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL267683 | 0.80 | — | — | |
| SCHEMBL4489846 | 0.80 | — | — | |
| SCHEMBL6233699 | 0.80 | — | — | |
| SCHEMBL28842884 | 0.80 | — | — | |
| SCHEMBL3342146 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL3508344 | 0.78 | — | — | |
| SCHEMBL15676022 | 0.78 | ALDH1A1 (0.38) | — | |
| SCHEMBL15676401 | 0.78 | ALDH1A1 (0.38) | — | |
| SCHEMBL13206280 | 0.77 | ALDH1A1 (0.41) | — | |
| SCHEMBL12261689 | 0.77 | ALDH1A1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3883931-A1 | HETEROCYCLIC COMPOUNDS AND MEDICAL USE THEREOF | Fondazione Telethon (IT) | 2021-09-29 | — | — | EP | claimed |
| US-12410164-B2 | Heterocyclic compounds and medical use thereof | FONDAZIONE TELETHON (IT) | 2025-09-09 | — | — | US | disclosed |
| CN-111867634-B | Enhancement of translocation of micro/nanoparticles across mucus layers using alginate oligomers | 阿尔吉法玛公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-3416956-B1 | METHYLAMINE DERIVATIVES AS LYSYL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2024-04-10 | — | — | EP | disclosed |
| US-11608330-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2023-03-21 | — | — | US | disclosed |
| US-20220002295-A1 | HETEROCYCLIC COMPOUNDS AND MEDICAL USE THEREOF | FONDAZIONE TELETHON (IT) | 2022-01-06 | — | — | US | disclosed |
| CN-109311839-B | Methylamine derivatives as lysyl oxidase inhibitors for the treatment of cancer | 癌症研究协会皇家癌症医院 | 2021-11-02 | — | — | CN | disclosed |
| EP-3883931-A1 | HETEROCYCLIC COMPOUNDS AND MEDICAL USE THEREOF | Fondazione Telethon (IT) | 2021-09-29 | — | — | EP | disclosed |
| US-10995088-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-05-04 | — | — | US | disclosed |
| US-20210040078-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-02-11 | — | — | US | disclosed |
| CN-111867634-A | Enhanced translocation of micro/nanoparticles across the mucus layer using alginate oligomers | 阿尔吉法玛公司 | 2020-10-30 | — | — | CN | disclosed |
| US-10807974-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-10-20 | — | — | US | disclosed |
| US-20190152966-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2019-05-23 | — | — | US | disclosed |
| EP-3416956-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | The Institute of Cancer Research : The Royal Cancer Hospital (GB) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017141049-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2017-08-24 | — | — | WO | disclosed |